Different therapeutic approaches on quality of life in patients with inflammatory bowel disease

BMC Gastroenterology

Research Article

Xu Feng¹  Hui Lin¹  Minyue Tang²  Jun Shen³  Zhihua Ran³  Junjie Xu⁴ 

[1] Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China;Department of Reproduction, Women's Hospital, Zhejiang University School of Medicine, 310006, Hangzhou, China;Division of Gastroenterology and Hepatology, State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology &Hepatology, Ministry of Health, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Cancer Institute,Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, 200001, Shanghai, China;Division of Gastroenterology and Hepatology, State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology &Hepatology, Ministry of Health, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Cancer Institute,Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, 200001, Shanghai, China;Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China;

关键词: Inflammatory bowel disease;    Health-related quality of life;    Inflammatory bowel disease questionnaire;    Infliximab;   

DOI  :  10.1186/s12876-014-0199-5

 received in 2014-07-28, accepted in 2014-11-10,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundThe chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated.MethodsConsecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment.ResultsMCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease economic burden (P = 0.048).ConclusionsMCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients. Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD.

【 授权许可】

Unknown   
© Xu et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.